ABSTRACT
The potential of radioimmunotherapy to selectively kill tumour cells is well established. However, optimisation is required with regards to increasing tumour localisation of antibodies. We used the PDGF-receptor inhibitor imatinib mesylate to improve tumour-specific antibody localisation in two models of colorectal adenocarcinoma and correlated antibody localisation with changes to tumour microvasculature. Mice bearing human colorectal xenografts (LS174T or SW1222) were treated with imatinib prior to administration of radiolabeled anti-CEA antibodies ((125)I-A5B7). Whole tumour and regional localisation of radiolabeled antibodies were measured. Microvessel density and pericyte coverage were quantified in whole tumours and correlated with (125)I-A5B7 localisation. Imatinib increased uptake of (125)I-A5B7 in LS174T but not SW1222 tumours after 48 h (p < 0.05). Imatinib reduced microvessel density in both models (p < 0.05) but reduced pericyte attachment to endothelial cells only in SW1222 xenografts (p < 0.05). Imatinib increases antibody distribution in LS174T tumours but not SW1222 tumours, and this correlated to changes in tumour microvessels. Accelerated clearance of radiolabeled antibody from normal tissues in both models resulted in enhanced tumour to normal tissue ratios. This improvement in tumour/normal tissue ratio has potential clinical benefit from a therapy and imaging perspective, and merits further investigation.
Subject(s)
Adenocarcinoma/therapy , Antibodies, Monoclonal/therapeutic use , Colorectal Neoplasms/therapy , Disease Models, Animal , Piperazines/therapeutic use , Pyrimidines/therapeutic use , Radioimmunotherapy , Receptor, Platelet-Derived Growth Factor beta/antagonists & inhibitors , Adenocarcinoma/immunology , Adenocarcinoma/metabolism , Adenocarcinoma/pathology , Animals , Antibodies, Monoclonal/pharmacokinetics , Antineoplastic Agents/therapeutic use , Benzamides , Carcinoembryonic Antigen/immunology , Colorectal Neoplasms/immunology , Colorectal Neoplasms/metabolism , Colorectal Neoplasms/pathology , Combined Modality Therapy , Female , Fluorescent Antibody Technique , Humans , Imatinib Mesylate , Immunoenzyme Techniques , Mice , Mice, Nude , Receptor, Platelet-Derived Growth Factor beta/metabolism , Tissue Distribution , Transplantation, HeterologousABSTRACT
PURPOSE: Antibody-directed enzyme prodrug therapy is a two-stage treatment whereby a tumor-targeted antibody-enzyme complex localizes in tumor for selective conversion of prodrug. The purpose of this study was to establish optimal variables for single administration of MFECP1, a recombinant antibody-enzyme fusion protein of an anti-carcinoembryonic antigen single-chain Fv antibody and the bacterial enzyme carboxypeptidase G2 followed by a bis-iodo phenol mustard prodrug. MFECP1 is manufactured in mannosylated form to facilitate normal tissue elimination. EXPERIMENTAL DESIGN: Pharmacokinetic, biodistribution, and tumor localization studies were used to test the hypothesis that MFECP1 localizes in tumor and clears from normal tissue via the liver. Firstly, safety of MFECP1 and a blood concentration of MFECP1 that would avoid systemic prodrug activation were tested. Secondly, dose escalation of prodrug was done. Thirdly, the dose of MFECP1 and timing of prodrug administration were optimized. RESULTS: MFECP1 was safe and well tolerated, cleared rapidly via the liver, and was less immunogenic than previously used products. Eighty-fold dose escalation from the starting dose of prodrug was carried out before dose-limiting toxicity occurred. Confirmation of the presence of enzyme in tumor and DNA interstrand cross-links indicating prodrug activation were obtained for the optimal dose and time point. A total of 28 of 31 patients was evaluable for response, the best response being a 10% reduction of tumor diameter, and 11 of 28 patients had stable disease. CONCLUSIONS: Optimal conditions for effective therapy were established. A study testing repeat treatment is currently being undertaken.
Subject(s)
Aniline Mustard/analogs & derivatives , Carcinoembryonic Antigen/immunology , Colorectal Neoplasms/drug therapy , Prodrugs/therapeutic use , Recombinant Fusion Proteins/therapeutic use , gamma-Glutamyl Hydrolase/therapeutic use , Aged , Aniline Mustard/blood , Aniline Mustard/pharmacokinetics , Aniline Mustard/therapeutic use , Antibodies, Monoclonal/blood , Antibodies, Monoclonal/therapeutic use , Antineoplastic Agents/blood , Antineoplastic Agents/pharmacokinetics , Antineoplastic Agents/therapeutic use , Dose-Response Relationship, Drug , Female , History, 16th Century , History, 17th Century , Humans , Imaging, Three-Dimensional , Immunoconjugates/blood , Immunoconjugates/pharmacokinetics , Immunoconjugates/therapeutic use , Male , Prodrugs/adverse effects , Prodrugs/pharmacokinetics , Recombinant Fusion Proteins/blood , Recombinant Fusion Proteins/pharmacokinetics , gamma-Glutamyl Hydrolase/blood , gamma-Glutamyl Hydrolase/pharmacokineticsABSTRACT
The 'magic bullet' concept predicted over a century ago that antibodies would be used to target cancer therapy. Since then initial problems that were related to specificity, purity and immungenicity of antibody-based reagents have slowly been overcome due to developments in technology and increased knowledge. As a result, antibodies are in use for many clinical applications and now comprise the second largest category of medicines in clinical development after vaccines. For antibody-based cancer therapeutics the last 20 years have met with an explosion of knowledge about the biology of the disease and potential targets as well as new technology which allows cloning and manipulation of multifunctional antibody-based molecules. However, the focus still remains on developing therapeutics that will have potential for treating cancer in people and this is efficiently assessed in mechanistic clinical trials that feed back to the laboratory for further development. This review illustrates the mechanistic approach to making new molecules for antibody imaging and therapy of cancer. It is illustrated by examples of radioimmunotherapy and antibody-directed enzyme prodrug therapy developed by the authors.